The Board stipulated that the company prior to the first day of listing must publish an approved prospectus and to raise at least NOK 3 million in additional capital. The Board authorised the Chief Executive Officer of Oslo Børs to fix the date of the first day of listing, which is to be no later than 19 August 2016.
Targovax is a clinical stage immuno-oncology company dedicated to the development of immunotherapies for cancer patients. Targovax is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and an oncolytic virus platform based on engineered viruses armed with potent immune-stimulating transgenes for patients with solid tumors. http://www.targovax.com/